Overview

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Olopatadine Hydrochloride
Ophthalmic Solutions